Namenda (memantine HCl) acts as an N-methyl-D-aspartate (NMDA) receptor antagonist designed to limit glutamate excitotoxicity and resulting neuronal damage [19,22,23]
These subjective changes translate to measurable reductions in daily caloric consumption, which can vary considerably between individuals
The American Society of Clinical Oncology recommends AGAINST its use for preventing chemotherapy-related nerve damage [28][29]
What to consider before starting a GLP-1 in perimenopause These are a few key factors to consider when deciding if GLP-1 is the right choice to manage your perimenopause weight gain: Body weight: The FDA approves GLP-1 medications primarily for individuals with a body mass index (BMI) of 30 or above, or a BMI of 27 or above alongside a weight-related health condition like high blood pressure or prediabetes
And every time I would bring up a new subject, it was like the is starting from scratch again to try to catch up
A Phase 2 RCT published in NEJM 2023 reported a mean body weight reduction of approximately 24% at 48 weeks with the 12 mg weekly dose in adults with obesity